CYP2C19 and depressive symptom measurement: Additional exploratory analysis measuring quality of life, anxiety and depression assessments was next analyzed to evaluate how CYP2D6/CYP2C19-C and CYP2D6/CYP2C19-I subgroups changed over the course of treatment.